Halozyme TherapeuticsHALO +1.67%92 PS Ratio is 6.58 as of Jul. 07, 2026, which is 38% below its 10-year median of 10.59. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 929 Biotechnology companies, Halozyme Therapeutics ranks better than 61.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Halozyme Therapeutics's share price is $80.78.
Halozyme Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $12.28. Hence, Halozyme Therapeutics's PS Ratio for today is 6.58.
The historical rank and industry rank for Halozyme Therapeutics's PS Ratio or its related term are showing as below:
HALO'
s PS Ratio Range Over the Past 10 Years
Min: 5.21 Med: 10.59 Max: 30.09
Current: 6.61
During the past 13 years, Halozyme Therapeutics's highest PS Ratio was 30.09. The lowest was 5.21. And the median was 10.59.
HALO's PS Ratio is ranked better than 61.03% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs HALO: 6.61
During the past 12 months, the average Revenue per Share Growth Rate of Halozyme Therapeutics was 45.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 33.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 41.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 27.00% per year.
During the past 13 years, Halozyme Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 232.20% per year. The lowest was -6.00% per year. And the median was 41.10% per year.
Back to Basics: PS Ratio
Halozyme Therapeutics (NAS:HALO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Halozyme Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Halozyme Therapeutics's Share Price of today is $80.78. Halozyme Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Halozyme Therapeutics (HALO) has a PS Ratio of 6.58 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Halozyme Therapeutics and its competitors. This is 38% below median its historical median of 10.59. Over the past decade, Halozyme Therapeutics' PS Ratio has ranged from 5.21 to 30.09. According to the industry distribution chart, Halozyme Therapeutics ranks #362 out of 929 companies in the Biotechnology industry, placing it in the top 39%.
Is Halozyme Therapeutics' PS Ratio too high?
Halozyme Therapeutics' current PS Ratio of 6.58 is 38% below median its 10-year median of 10.59. Over the past 10 years, this metric has ranged from a low of 5.21 to a high of 30.09. The Biotechnology industry median PS Ratio is 9.91. Halozyme Therapeutics' value of 6.58 is 33.6% below this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #362 out of 929 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' PS Ratio compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #362 out of 929 companies for PS Ratio. This puts Halozyme Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.91. Halozyme Therapeutics' value of 6.58 is 33.6% below this benchmark. Historically, Halozyme Therapeutics' own PS Ratio has ranged from 5.21 to 30.09 over the past decade. While the company's 10-year median is 10.59 vs. the industry median of 9.91, Halozyme Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current PS Ratio of 6.58 is 33.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current PS Ratio is 6.58, which is 38% below median its own 10-year median of 10.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.87, compared to a current price of $80.78 — trading 11.1% below its estimated fair value. The current PS Ratio is 6.58, which is 38% below median its 10-year median of 10.59 and 33.6% below the Biotechnology industry median of 9.91. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current PS Ratio is 6.58 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $80.78 is trading 11.1% below its estimated GF Value™ of $90.87.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
PS Ratio: 6.58 (38% below median its 10-year median of 10.59)
GF Value™: $90.87 vs. price of $80.78 (11.1% below fair value)
Industry Position: 33.6% below the Biotechnology median (#362 of 929)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
